![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CLU |
Gene summary for CLU |
![]() |
Gene information | Species | Human | Gene symbol | CLU | Gene ID | 1191 |
Gene name | clusterin | |
Gene Alias | AAG4 | |
Cytomap | 8p21.1 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P10909 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1191 | CLU | GSM4909282 | Human | Breast | IDC | 3.33e-34 | -8.49e-01 | -0.0288 |
1191 | CLU | GSM4909285 | Human | Breast | IDC | 5.64e-39 | -8.76e-01 | 0.21 |
1191 | CLU | GSM4909288 | Human | Breast | IDC | 3.98e-03 | -3.45e-01 | 0.0988 |
1191 | CLU | GSM4909290 | Human | Breast | IDC | 2.17e-38 | -9.43e-01 | 0.2096 |
1191 | CLU | GSM4909293 | Human | Breast | IDC | 2.68e-14 | -5.99e-01 | 0.1581 |
1191 | CLU | GSM4909294 | Human | Breast | IDC | 1.78e-10 | -4.40e-01 | 0.2022 |
1191 | CLU | GSM4909296 | Human | Breast | IDC | 6.83e-33 | -7.74e-01 | 0.1524 |
1191 | CLU | GSM4909297 | Human | Breast | IDC | 3.03e-10 | -2.40e-01 | 0.1517 |
1191 | CLU | GSM4909298 | Human | Breast | IDC | 1.61e-07 | -5.29e-01 | 0.1551 |
1191 | CLU | GSM4909299 | Human | Breast | IDC | 3.59e-17 | 5.67e-01 | 0.035 |
1191 | CLU | GSM4909300 | Human | Breast | IDC | 9.03e-05 | 4.60e-01 | 0.0334 |
1191 | CLU | GSM4909301 | Human | Breast | IDC | 1.76e-22 | -7.36e-01 | 0.1577 |
1191 | CLU | GSM4909304 | Human | Breast | IDC | 8.74e-22 | -7.57e-01 | 0.1636 |
1191 | CLU | GSM4909311 | Human | Breast | IDC | 5.72e-38 | -7.49e-01 | 0.1534 |
1191 | CLU | GSM4909312 | Human | Breast | IDC | 1.55e-32 | -7.91e-01 | 0.1552 |
1191 | CLU | GSM4909313 | Human | Breast | IDC | 3.75e-02 | 1.83e-01 | 0.0391 |
1191 | CLU | GSM4909315 | Human | Breast | IDC | 2.63e-04 | -3.33e-01 | 0.21 |
1191 | CLU | GSM4909316 | Human | Breast | IDC | 4.55e-04 | -5.96e-01 | 0.21 |
1191 | CLU | GSM4909318 | Human | Breast | IDC | 2.93e-05 | -7.64e-01 | 0.2031 |
1191 | CLU | GSM4909319 | Human | Breast | IDC | 2.47e-39 | -4.32e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006113615 | Cervix | HSIL_HPV | regulation of proteasomal protein catabolic process | 16/737 | 187/18723 | 3.01e-03 | 2.78e-02 | 16 |
GO:000863714 | Cervix | HSIL_HPV | apoptotic mitochondrial changes | 11/737 | 107/18723 | 3.27e-03 | 2.97e-02 | 11 |
GO:009008313 | Cervix | HSIL_HPV | regulation of inclusion body assembly | 4/737 | 17/18723 | 3.76e-03 | 3.30e-02 | 4 |
GO:003133314 | Cervix | HSIL_HPV | negative regulation of protein-containing complex assembly | 13/737 | 141/18723 | 3.80e-03 | 3.32e-02 | 13 |
GO:00454297 | Cervix | HSIL_HPV | positive regulation of nitric oxide biosynthetic process | 6/737 | 40/18723 | 4.46e-03 | 3.75e-02 | 6 |
GO:1902230 | Cervix | HSIL_HPV | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 5/737 | 29/18723 | 5.05e-03 | 4.12e-02 | 5 |
GO:19044077 | Cervix | HSIL_HPV | positive regulation of nitric oxide metabolic process | 6/737 | 41/18723 | 5.06e-03 | 4.12e-02 | 6 |
GO:004580714 | Cervix | HSIL_HPV | positive regulation of endocytosis | 10/737 | 100/18723 | 6.00e-03 | 4.72e-02 | 10 |
GO:200123325 | Cervix | N_HPV | regulation of apoptotic signaling pathway | 36/534 | 356/18723 | 4.95e-11 | 5.63e-08 | 36 |
GO:009719325 | Cervix | N_HPV | intrinsic apoptotic signaling pathway | 31/534 | 288/18723 | 2.39e-10 | 2.17e-07 | 31 |
GO:200124225 | Cervix | N_HPV | regulation of intrinsic apoptotic signaling pathway | 23/534 | 164/18723 | 2.93e-10 | 2.21e-07 | 23 |
GO:00024432 | Cervix | N_HPV | leukocyte mediated immunity | 39/534 | 440/18723 | 3.94e-10 | 2.24e-07 | 39 |
GO:000695921 | Cervix | N_HPV | humoral immune response | 31/534 | 317/18723 | 2.53e-09 | 7.88e-07 | 31 |
GO:000246021 | Cervix | N_HPV | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 33/534 | 356/18723 | 2.99e-09 | 8.02e-07 | 33 |
GO:000181922 | Cervix | N_HPV | positive regulation of cytokine production | 38/534 | 467/18723 | 7.18e-09 | 1.58e-06 | 38 |
GO:000244911 | Cervix | N_HPV | lymphocyte mediated immunity | 32/534 | 350/18723 | 7.29e-09 | 1.58e-06 | 32 |
GO:200124323 | Cervix | N_HPV | negative regulation of intrinsic apoptotic signaling pathway | 16/534 | 98/18723 | 1.68e-08 | 2.55e-06 | 16 |
GO:200123425 | Cervix | N_HPV | negative regulation of apoptotic signaling pathway | 23/534 | 224/18723 | 1.22e-07 | 1.15e-05 | 23 |
GO:000645724 | Cervix | N_HPV | protein folding | 22/534 | 212/18723 | 1.90e-07 | 1.57e-05 | 22 |
GO:006107723 | Cervix | N_HPV | chaperone-mediated protein folding | 12/534 | 67/18723 | 3.68e-07 | 2.54e-05 | 12 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLU | SNV | Missense_Mutation | novel | c.1199C>T | p.Ser400Phe | p.S400F | P10909 | protein_coding | deleterious(0) | possibly_damaging(0.708) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
CLU | SNV | Missense_Mutation | novel | c.862N>G | p.Ile288Val | p.I288V | P10909 | protein_coding | deleterious(0.04) | possibly_damaging(0.524) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CLU | SNV | Missense_Mutation | novel | c.58N>T | p.Val20Phe | p.V20F | P10909 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-V7-A7HQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | letrozole | CR |
CLU | SNV | Missense_Mutation | c.139N>A | p.Gln47Lys | p.Q47K | P10909 | protein_coding | tolerated(0.31) | benign(0.005) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CLU | SNV | Missense_Mutation | c.1027N>A | p.Glu343Lys | p.E343K | P10909 | protein_coding | tolerated(0.23) | possibly_damaging(0.503) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CLU | SNV | Missense_Mutation | rs769830551 | c.679C>T | p.Arg227Cys | p.R227C | P10909 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
CLU | SNV | Missense_Mutation | rs146625005 | c.1135N>A | p.Glu379Lys | p.E379K | P10909 | protein_coding | tolerated(0.5) | benign(0.195) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
CLU | SNV | Missense_Mutation | c.236N>T | p.Lys79Met | p.K79M | P10909 | protein_coding | tolerated(0.08) | probably_damaging(0.995) | TCGA-AA-A02O-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CLU | SNV | Missense_Mutation | novel | c.98N>G | p.Glu33Gly | p.E33G | P10909 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CLU | SNV | Missense_Mutation | c.657N>G | p.Phe219Leu | p.F219L | P10909 | protein_coding | tolerated(0.77) | benign(0.015) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1191 | CLU | CELL SURFACE, DRUGGABLE GENOME | OGX-011 | CUSTIRSEN SODIUM | ||
1191 | CLU | CELL SURFACE, DRUGGABLE GENOME | antisense oligonucleotide | CUSTIRSEN | CUSTIRSEN | |
1191 | CLU | CELL SURFACE, DRUGGABLE GENOME | PMSG | 1547735 | ||
1191 | CLU | CELL SURFACE, DRUGGABLE GENOME | inhibitor | OGX-011 | CUSTIRSEN SODIUM | |
1191 | CLU | CELL SURFACE, DRUGGABLE GENOME | LUBIPROSTONE | LUBIPROSTONE |
Page: 1 |